Circulating intercellular adhesion molecule-1 and E-selectin levels in gastric cancer. 1998

M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
Institute of Oncology, Hacettepe University School of Medicine, Ankara, Turkey.

A diversity of adhesive interactions occur between the cancer cell and host extracellular matrix which potentiate neoplastic expansion and metastatic dissemination. In miscellaneous malignant diseases, tumour progression has been observed to be associated with alterations in adhesion molecule expression. Recently, circulating soluble intercellular adhesion molecules have been identified. In this study, serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble E-selectin (sE-selectin) were determined in patients with gastric cancer. The study group consisted of 27 patients with previously untreated gastric adenocarcinoma. Four patients had stage II, two patients stage III and 21 patients stage IV disease according to the TNM classification. Nineteen patients had distant metastasis. The sera obtained from 18 healthy volunteers served as controls. Serum sICAM-1 and sE-selectin concentrations were determined by enzyme-linked immunosorbent assay (ELISA). In addition, we also studied other tumour-associated antigens, i.e. CEA and CA 19-9. Serum sICAM-1 levels were significantly increased in patients with gastric cancer (P < 0.0001). However, sE-selectin levels did not differ from the controls. sICAM-1 concentrations were also significantly higher in patients with distant metastasis and peritoneal spread (P = 0.0045 and P = 0.0157 respectively), whereas sE-Selectin levels were elevated only in patients with peritoneal metastasis (P = 0.033). Serum concentrations of sICAM-1 and sE-selectin correlated with CEA levels (P = 0.0013 and P = 0.003 respectively). Elevated levels of sE-selectin were associated with poorer prognosis (P = 0.0099), whereas sICAM-1 had no significant impact on survival. Our results suggest that increased sICAM-1 serum levels may reflect widespread disease and contribute directly to the progression of gastric cancer. Further investigation of the molecular mechanisms of adhesive tumour-host interactions may lead to a better understanding of the natural history of gastric cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
January 1997, British journal of cancer,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
January 1998, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
February 2003, The American journal of gastroenterology,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
January 1999, British journal of cancer,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
September 2000, The Journal of rheumatology,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
March 2001, Indian journal of cancer,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
July 1993, British journal of cancer,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
June 1996, Chest,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
September 2012, Journal of gastric cancer,
M Benekli, and I H Güllü, and G Tekuzman, and M C Savaş, and M Hayran, and G Hasçelik, and D Firat
November 1999, Diabetes research and clinical practice,
Copied contents to your clipboard!